Is tezepelumab the ubiquitous biologic for severe asthma?

Richard Beasley; Anne B. Chang

doi:10.1016/S2213-2600(22)00530-6

Is tezepelumab the ubiquitous biologic for severe asthma?

Richard Beasley, Anne B. Chang

Child and Maternal Health

Research output: Contribution to journal › Comment/debate › peer-review

1 Citation (Scopus)

Abstract

[No abstract]

Original language	English
Pages (from-to)	393-395
Number of pages	3
Journal	The Lancet Respiratory Medicine
Volume	11
Issue number	5
Early online date	23 Jan 2023
DOIs	https://doi.org/10.1016/S2213-2600(22)00530-6
Publication status	Published - May 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S2213-2600(22)00530-6

Cite this

@article{989d771d8412481f8c22b22d3fd27465,

title = "Is tezepelumab the ubiquitous biologic for severe asthma?",

abstract = "[No abstract]",

author = "Richard Beasley and Chang, {Anne B.}",

year = "2023",

month = may,

doi = "10.1016/S2213-2600(22)00530-6",

language = "English",

volume = "11",

pages = "393--395",

journal = "The Lancet Respiratory Medicine",

issn = "2213-2600",